Cardiology

The HF Stats 2026 report examines US heart failure trends, highlighting rising mortality, younger patients, and gaps in treatment.

HFSA 2026 will spotlight late-breaking trials in heart failure drugs, amyloidosis imaging, cardiomyopathy, and device-based care.

Study compares the American Heart Association/American College of Cardiology/multisociety 2026 and 2018 lipid guidelines to assess changes in US eligibility for primary prevention statin therapy.

In a post hoc analysis of the randomized CLEAR Outcomes trial, bempedoic acid 180 mg reduced first major adverse limb events (MALE) by 36% and total MALE by 45% versus placebo among statin-intolerant...

In an open-label extension, cliramitug reduced cardiac amyloid markers over a median 29.3 months in 23 men with ATTR-CM.

In a multisite nonrandomized trial, AI-guided screening identified ATTR-CM in 24 of 50 patients who completed diagnostic testing.

In a prespecified secondary analysis of the phase 3 SELECT trial, once-weekly semaglutide 2.4 mg reduced high-sensitivity C-reactive protein by 37.8% versus placebo at 104 weeks among adults with...

In a post hoc analysis of the phase 3 HELIOS-B trial, vutrisiran reduced worsening of left atrial strain at 30 months among patients with transthyretin amyloidosis with cardiomyopathy.

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

Experts discuss how the 2025 ACC/AHA blood pressure guidelines may affect hypertension treatment decisions.